Timothy Edwards

Cellzome AG provides drug discovery services. It is a research company with proprietary proteomics technology for target and lead identification and a drug discovery program in Alzheimer's disease. The company was founded in 2000 and is headquartered in Heidelberg, Germany.

Cellzome Ltd. engages in the research, development, and manufacture of pharmaceutical products. It provides kinase-targeted drugs to treat inflammatory diseases. The company was founded by Gitte Neubauer on December 22, 2003 and is headquartered in Middlesex, the United Kingdom.

ReOx Ltd. discovers and develops drugs. It provides novel treatments for disease by controlling the actvity of hypoxia inducible factor. The company was founded by Christopher W. Pugh, Patrick Maxwell, Peter J. Ratcliffe, and Christopher J. Schofield in June 2003 and is headquartered in Thame, the United Kingdom.

Ligand UK Ltd. is a commercial stage pharmaceutical company. Its products include Tuzistra XR, targeting the U.S. prescription cough-cold market, Moxatag, a once-a-day formulation of the antibiotic and amoxicillin, and frovatriptan, used for the acute treatment of migraine. It also develops and commercializes multiple novel products focused on the U.S. prescription cough-cold market. The company was founded by Keith G. McCullagh and Andre L. Lamotte in 1988 and is headquartered in Winnersh, the United Kingdom.

The BioIndustry Association is a UK-based organization that represents the life sciences and biotech industry. The British company's mission is to facilitate and connect the ecosystem to help businesses start, grow, and deliver world-changing innovation. The non-profit company was founded by Cormac G. Kilty and Simon Geoffrey Best, and Steve Bates has been the CEO of the company since 2012.

The Mulberry Bush Organisation Ltd. is a UK-based charity that provides specialist therapeutic services to transform the lives of all those affected by childhood trauma. The Mulberry Bush also offers a 'haven and reflective space' for meaningful experiences located in Toddington, Gloucestershire, called MB3. The heart of the charity's practice expertise is the Mulberry Bush School in Standlake, Oxfordshire. The charity is committed to research in therapeutic residential and foster care. The Mulberry Bush Outreach Service provides training, consultation, and support to schools, care services, and organizations working with challenging or vulnerable children, their families, and communities. The charity is committed to being a forward-thinking charity for the sector in minimizing the impact of its activities on the environment. The Mulberry Bush relies on donations for building improvements, outreach services, research, new service developments, or any of the fun, extra-curricular activities that emotionally-traumatized children so desperately need. The charity was founded in 1948 by Barbara Dockar-Drysdale, and the CEO is John Diamond.

ProtAffin was spun out of the Karl-Franzens University of Graz in July 2005. The company currently employs 16 people in modern office and laboratory facilities in Graz and Vienna and plans to expand to 27 by the end of 2009. They are well financed by a syndicate of 5 international venture capital investors. The company has a balanced 'platform-product' strategy: a lead compound in pre-clinical development and a core discovery technology by which they are supporting a sustainable pipeline of products via its unique CellJammer® discovery technology platform. ProtAffin is leveraging its leading technical expertise in protein-glycan interactions to develop novel biological products. They are currently collaborating with a number of university groups in Austria, Germany, Brazil and the UK. They plan to collaborate with Pharma and Biotech companies interested to access its technology for the development of novel anti-inflammatory products with a unique mechanism of action.

Oxagen Ltd. develops novel molecule drugs to treat inflammatory and respiratory diseases. It offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhino conjunctivitis. The company was founded by Nick Cross, John Irving Bellin, Mark Edwards, Trevor J. Nicholls and Ian Michael Laing on September 05 1996 and is headquartered in London, the United Kingdom.